Abstract

Anomalous expression of micro RNAs (miRNAs) and circular RNAs (circRNAs) were strongly correlated to the progression of multiple cancers, including multiple myeloma (MM). This study aimed to investigate whether circ_0008035 exerts its roles on MM cells by targetingmiRNA-1256. To analyze the levels of circ_0008035 and miRNA-1256 in MM samples and healthy bone marrow samples, a real time quantitative PCR (RT-qPCR) assay was executed. Cell proliferation and apoptosis were detected with a cell counting kit (CCK-8) and flow cytometry assay, respectively. The cell invasive and migration ability were assessed using a transwell assay. Dual-luciferase reporter assay and RTqPCR were applied to analyze and compare the targeting effect of circ_0008035 and miRNA-1256. Circ_0008035 was overexpressed, while miRNA-1256 expression declined in MM bone marrow tissues. RPMI8226 cells transfected with si-circ_0008035 or miRNA-1256 mimic exhibited lower proliferation and migration capabilities, while cell apoptosis was remarkably elevated. Circ_0008035 acts as a miRNA-1256sponge and negatively controls miRNA-1256 expression. Transfection of anti-miRNA-1256 reversed proliferation and migration inhibition and promoted cell apoptosis, which was motivated by si-circ_0008035 transfection. Circ_0008035 negatively regulated miRNA-1256, and the circ_0008035/miRNA-1256 axis regulates the progression of MM, thus providing a potential target for MM therapy.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.